Cagrilintide Dosage Guide: Forms, Protocol Claims and Safety Questions

Exact studied weekly doses and where they come from

Cagrilintide is a long‑acting amylin analogue investigated for weight management. The pivotal phase 2 dose‑ranging trial in adults with overweight or obesity (without diabetes) tested once‑weekly cagrilintide at 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg and 4.5 mg versus placebo. These are the specific dose levels commonly referenced in summaries and clinic protocols.

In combination studies with semaglutide (“CagriSema”), the cagrilintide component targeted 2.4 mg weekly after escalation, paired with semaglutide 2.4 mg weekly after its standard step‑up schedule.

Representative titration schedule used in trials

Dose escalation in trials followed a “start low, go slow” approach to reduce gastrointestinal (GI) adverse events:

• Weeks 1–4: 0.3 mg once weekly
• Weeks 5–8: 0.6 mg once weekly
• Weeks 9–12: 1.2 mg once weekly
• Weeks 13–16: 2.4 mg once weekly
• Beyond week 16: up‑titrate toward 4.5 mg once weekly if additional effect desired and tolerated

Important: This schedule is provided to illustrate the trial‑style “step‑up” pattern. Do not self‑dose. Real‑world decisions (starting level, step size, and whether to stop escalation) must be made by your prescribing clinician based on your medical history and tolerability.

Get a clinician-built titration plan

CagriSema (cagrilintide + semaglutide): doses and titration used

Trials that combined cagrilintide with semaglutide (“CagriSema”) generally:

• Escalated cagrilintide from 0.3 mg weekly in stepwise fashion to 2.4 mg weekly.
• Escalated semaglutide using the familiar Wegovy‑style schedule: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, changing roughly every 4 weeks as tolerated.
• Maintained both components once weekly thereafter.

Populations and endpoints:

• Obesity without diabetes: focused on percent weight change and tolerability.
• Type 2 diabetes: evaluated weight change alongside glycaemic endpoints (e.g., HbA1c), using the same target combo dose (2.4 mg + 2.4 mg) following step‑up.

Compare mechanisms and dose strategies: cagrilintide vs semaglutide

Why weekly? Core pharmacokinetics

• Half‑life: approximately 7 days (about 160–170 hours) after subcutaneous dosing, enabling once‑weekly administration.
• Steady state: typically reached in ~4–5 weeks, so appetite/satiety effects and GI tolerability often stabilise after the first month.
• Exposure: step‑up titration mitigates peak‑related nausea and allows time for the GI tract to adapt.

Discuss timing and expectations

Missed‑dose guidance from trial protocols

Trial documents typically instructed participants who missed a weekly cagrilintide dose to:

• Administer the missed dose within approximately 3 days (72 hours) of the scheduled time, then resume the usual weekly schedule.
• If more than ~3 days had passed, skip the missed dose and take the next dose at the regular scheduled time.
• Do not double the next dose to “catch up”.

For CagriSema, prescribers often reference semaglutide labelling (which allows a longer catch‑up window), but you should follow your clinician’s exact instructions to keep both components synchronised.

Always follow the plan provided by your prescriber. If you have vomited a dose or are unsure whether an injection was complete, contact your clinic for individual advice.

Ask about your missed‑dose scenario

Forms available and common protocol claims

In Australia, cagrilintide is not an approved, registered medicine at the time of writing. Any access would occur through clinical trials or carefully governed unapproved‑product pathways. Be cautious with grey‑market products claiming “cagrilintide” without provenance—dose labels may not reflect the compound, concentration, or sterility.

• Clinic protocols may mirror trial dose levels (0.3→0.6→1.2→2.4→4.5 mg weekly) and pause escalation if GI symptoms persist.
• CagriSema claims usually refer to a 2.4 mg + 2.4 mg once‑weekly maintenance target, reached by 4‑week step‑ups for each component.

Learn more: Is cagrilintide legal in Australia?

Which populations the dose ranges refer to

• Obesity without diabetes: the 0.3–4.5 mg weekly range comes from the phase 2 dose‑ranging study in adults with overweight/obesity and no diabetes.
• Type 2 diabetes: cagrilintide has primarily been studied in combination with semaglutide (CagriSema). The target maintenance combo was 2.4 mg + 2.4 mg weekly after escalation; outcomes included weight and HbA1c.
• Not evaluated as a mealtime agent for type 1 diabetes: dosing is fundamentally different from pramlintide (see below).

Cagrilintide for obesity: what trials show

How cagrilintide compares numerically to pramlintide

Pramlintide is a short‑acting amylin analogue used at mealtimes in diabetes. Typical adult dosing is in micrograms (mcg), not milligrams (mg):

• Type 1 diabetes: 15 mcg pre‑meal, titrating to 30–60 mcg pre‑meal if tolerated (three times daily with major meals).
• Type 2 diabetes: 60 mcg pre‑meal, titrating to 120 mcg pre‑meal (three times daily).

By contrast, cagrilintide is long‑acting and dosed once weekly in milligrams (e.g., 1.2–2.4 mg maintenance in trials, up to 4.5 mg). The large difference in units and frequency reflects distinct pharmacokinetics and use cases.

Ask a clinician which class, if any, suits your profile

When to pause titration and key safety watch‑outs

• Pause escalation if moderate/severe nausea, vomiting, abdominal pain, or dehydration occurs; re‑attempt a lower step once symptoms resolve per prescriber advice.
• Constipation can occur; ensure adequate hydration and fibre intake as advised by your clinician.
• Potential additive GI effects when combined with GLP‑1 RAs (e.g., semaglutide); slower step‑ups are common.
• Seek urgent care for severe, persistent abdominal pain (pancreatitis warning applies across appetite‑modulating injectables).

See more: Cagrilintide side effects

Frequently asked questions (concise, numeric answers)

Next steps

• Cagrilintide benefits: what’s supported so far
• Results timeline: when changes were seen
• Side effects and warnings
• Buy cagrilintide in Australia: safer routes
• Cagrilintide cost in Australia
• Prescription requirements in Australia
• How to read cagrilintide reviews
• Before & after claims: what they show
• Cagrilintide vs semaglutide
• Cagrilintide vs tirzepatide

Talk to a clinician about your options

Get help from a licensed provider

Send a secure message and a clinician‑led team will respond about eligibility, dosing questions, and next steps.

Prefer to browse? See our overview of weight loss injections in Australia and the GLP‑1 Australia guide.

Final takeaway

The best‑documented cagrilintide dosage information comes from trials that used weekly doses of 0.3, 0.6, 1.2, 2.4 and 4.5 mg with 4‑week step‑ups—either as monotherapy or, in the case of CagriSema, alongside semaglutide titrated to 2.4 mg. Weekly dosing is supported by a ~7‑day half‑life and steady state at ~4–5 weeks.

Dosing is medical, individual and safety‑critical—use a prescriber‑built plan and pause escalation if tolerability is not satisfactory.

Get safe, individual advice